Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:THTX - CA88338H7040 - Common Stock

3.39 USD
0 (0%)
Last: 9/25/2025, 8:03:14 PM
3.4 USD
+0.01 (+0.29%)
After Hours: 9/25/2025, 8:03:14 PM
Fundamental Rating

3

Overall THTX gets a fundamental rating of 3 out of 10. We evaluated THTX against 533 industry peers in the Biotechnology industry. There are concerns on the financial health of THTX while its profitability can be described as average. THTX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

THTX had negative earnings in the past year.
THTX had a positive operating cash flow in the past year.
In the past 5 years THTX always reported negative net income.
In the past 5 years THTX reported 4 times negative operating cash flow.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.86%, THTX is in the better half of the industry, outperforming 79.10% of the companies in the same industry.
THTX has a Return On Invested Capital of 55.37%. This is amongst the best in the industry. THTX outperforms 99.44% of its industry peers.
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROIC 55.37%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

THTX has a better Operating Margin (10.05%) than 92.35% of its industry peers.
Looking at the Gross Margin, with a value of 77.72%, THTX belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.
THTX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.05%
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

THTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, THTX has about the same amount of shares outstanding.
The number of shares outstanding for THTX has been reduced compared to 5 years ago.
The debt/assets ratio for THTX is higher compared to a year ago.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -8.27, we must say that THTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.27, THTX is not doing good in the industry: 70.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.27
ROIC/WACC4.64
WACC11.93%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

THTX has a Current Ratio of 0.84. This is a bad value and indicates that THTX is not financially healthy enough and could expect problems in meeting its short term obligations.
THTX has a Current ratio of 0.84. This is amonst the worse of the industry: THTX underperforms 89.37% of its industry peers.
A Quick Ratio of 0.65 indicates that THTX may have some problems paying its short term obligations.
THTX's Quick ratio of 0.65 is on the low side compared to the rest of the industry. THTX is outperformed by 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.65
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for THTX have decreased by 0.00% in the last year.
The Revenue has been growing slightly by 2.19% in the past year.
THTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.31% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%

3.2 Future

The Earnings Per Share is expected to grow by 29.71% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 3.44% on average over the next years.
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

THTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 24.08, THTX is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of THTX indicates a rather cheap valuation: THTX is cheaper than 91.79% of the companies listed in the same industry.
THTX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 24.08
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, THTX is valued cheaply inside the industry as 94.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.18
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
THTX's earnings are expected to grow with 46.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.79%
EPS Next 3Y46.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

NASDAQ:THTX (9/25/2025, 8:03:14 PM)

After market: 3.4 +0.01 (+0.29%)

3.39

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-09 2025-07-09/bmo
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners22.29%
Inst Owner Change-50.87%
Ins Owners0.9%
Ins Owner ChangeN/A
Market Cap155.87M
Revenue(TTM)84.38M
Net Income(TTM)-9.16M
Analysts84
Price Target4.09 (20.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-291.26%
Min EPS beat(2)-482.52%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-224.76%
Min EPS beat(4)-482.52%
Max EPS beat(4)94.17%
EPS beat(8)5
Avg EPS beat(8)-62.95%
EPS beat(12)6
Avg EPS beat(12)-46.18%
EPS beat(16)6
Avg EPS beat(16)-49.02%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)-1.91%
Revenue beat(4)1
Avg Revenue beat(4)-3.24%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-5.3%
Revenue beat(12)1
Avg Revenue beat(12)-6.15%
Revenue beat(16)1
Avg Revenue beat(16)-7.55%
PT rev (1m)0.63%
PT rev (3m)-1.02%
EPS NQ rev (1m)-166.67%
EPS NQ rev (3m)-125%
EPS NY rev (1m)0%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)-7.92%
Revenue NQ rev (3m)-10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.08
P/S 1.85
P/FCF N/A
P/OCF 22.15
P/B N/A
P/tB N/A
EV/EBITDA 18.18
EPS(TTM)-0.19
EYN/A
EPS(NY)0.14
Fwd EY4.15%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0.15
OCFY4.51%
SpS1.84
BVpS-0.61
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROCE 70.09%
ROIC 55.37%
ROICexc 307.38%
ROICexgc N/A
OM 10.05%
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score4
Asset Turnover1.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.84
Cap/Depr 519.63%
Cap/Sales 11.98%
Interest Coverage 1.21
Cash Conversion 67.47%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.65
Altman-Z -8.27
F-Score4
WACC11.93%
ROIC/WACC4.64
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%
EBIT growth 1Y125.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y28.68%
FCF growth 1Y82.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.06%
OCF growth 3YN/A
OCF growth 5YN/A

THERATECHNOLOGIES INC / THTX FAQ

What is the fundamental rating for THTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to THTX.


What is the valuation status for THTX stock?

ChartMill assigns a valuation rating of 4 / 10 to THERATECHNOLOGIES INC (THTX). This can be considered as Fairly Valued.


What is the profitability of THTX stock?

THERATECHNOLOGIES INC (THTX) has a profitability rating of 4 / 10.


How financially healthy is THERATECHNOLOGIES INC?

The financial health rating of THERATECHNOLOGIES INC (THTX) is 1 / 10.